医学
格列本脲
糖尿病
胰岛素
血糖性
内科学
内分泌学
代谢控制分析
2型糖尿病
作者
Ferda Evin,Esra Işık,Hüseyin Önay,Samim Özen,Şükran Darcan,Damla Gökşen
标识
DOI:10.1515/jpem-2022-0642
摘要
Abstract Objectives Activating variants of the ABCC8 gene cause neonatal diabetes or maturity-onset diabetes of the young (MODY). We report three cases of MODY type 12 caused by variants in the ABCC8 encoding sulphonylurea receptor 1, and the experience of switching from insulin therapy to sulphonylurea therapy. Case presentations We describe a 12.5-year-old girl with permanent neonatal diabetes mellitus, and two diabetes mellitus cases with variants in the ABCC8 gene. Two of these cases were successfully switched from subcutaneous insulin to oral glibenclamide, with a marked improvement in glycemic control. In permanent neonatal diabetes case, glibenclamide dose was progressively increased to achieve a full dose (2 mg/kg/day) in 9 days. Nine months after starting oral sulphonylurea therapy, her blood glucose control dramatically improved and insulin therapy was discontinued. Conclusions We conclude that patients with ABCC8 gene variants can successfully switch from insulin to sulphonylureas.
科研通智能强力驱动
Strongly Powered by AbleSci AI